The inhibition of prolactin release using the dopamine antagonist, bromocriptine, prevents the development of peripartum cardiomyopathy in mice, suggesting a potential role of prolactin in the pathogenesis of the disease (252, 253). Here, PRL is linked to peripartum cardiomyopathy.